CTSO
Cytosorbents Corporation
NASDAQ · USHealthcareMedical - Devices
$0.38+5.58%
Price as of Jul 20, 2026
CTSO financials
Cytosorbents Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M |
| Cost of revenue | $10.6M | $10.7M | $9.1M | $14.0M |
| Gross profit | $26.5M | $24.9M | $22.0M | $20.7M |
| Operating expenses | $40.7M | $41.3M | $53.9M | $52.3M |
| Operating income | -$14.2M | -$16.5M | -$31.9M | -$31.5M |
| Net income | -$8.2M | -$20.7M | -$29.2M | -$32.8M |
| EBITDA | -$4.4M | -$19.3M | -$27.9M | -$30.0M |
| Basic EPS | $-0.13 | $-0.38 | $-0.65 | $-0.75 |
| Diluted EPS | $-0.13 | $-0.38 | $-0.65 | $-0.75 |
| Balance sheet | ||||
| Cash & equivalents | $6.2M | $3.3M | $14.1M | $22.1M |
| Total assets | $44.2M | $47.4M | $53.3M | $63.2M |
| Total liabilities | $38.3M | $36.3M | $30.0M | $27.9M |
| Stockholders’ equity | $5.9M | $11.1M | $23.3M | $35.4M |
| Total debt | $29.1M | $26.9M | $18.3M | $18.3M |
| Net debt | $22.9M | $23.6M | $4.2M | -$3.9M |
| Cash flow | ||||
| Operating cash flow | -$12.4M | -$14.4M | -$21.7M | -$28.2M |
| Capital expenditure | -$164.0K | -$284.3K | -$936.2K | -$6.5M |
| Free cash flow | -$12.5M | -$14.7M | -$22.6M | -$34.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |